Enable Accessibility Enable Accessibility

Our Worldview

Understanding and responding to a rapidly changing world
Change is the only constant in our industry, and across society globally. Anticipating change, turning it into opportunity and staying ahead of the curve are essential to running a sustainable business.

Meeting our responsibilities
As one of the world’s top 10 biopharmaceutical companies, Takeda fully understands its responsibilities to patients, employees, shareholders, payors, regulators and governments, as well as the communities where we operate. We can only earn the acceptance, respect and trust of society if we take these responsibilities seriously.

Part of this commitment is to be one step ahead of change that’s taking place in an increasingly complex and volatile world. We need to understand and respond to the trends that are shaping our marketplace, including the challenges faced by the people who ultimately rely on our medicines and vaccines.

To create long-lasting value for society, we must be agile enough to take advantage of the opportunities these changes present. We must also guard against the threats they pose. At all times, we need to make sure our actions and decisions are based on our values, and that we have a positive impact on Patients, People and the Planet. Here are some of the most important issues affecting our business today, and what we’re doing about them.

OurWorldview

Global Population Growth

Populations are growing and aging globally. This has a direct impact on our business and presents clear opportunities in terms of expanding markets and increased demand for health care. We believe in Universal Access to Health. And we recognize that the private sector, particularly the pharmaceutical industry, can play an essential role in helping achieve this goal by shifting from an ecosystem approach to partnership building. A wide variety of stakeholders should align to find practical solutions to complex health care challenges. All our actions must be centered on placing patients first and enabling communities to rally for health as a human right.

We recognize that health care systems are often not perfect. That’s why we’re doing our part to help ensure our medicines and vaccines reach the people who need them. Our Blueprint for Innovative Health Care Access pilot program in Kenya, for example, is an integrated, sustainable implementation framework aimed at strengthening health care systems. It focuses on noncommunicable diseases at every stage of the patient journey. It also includes programs to increase patient access.

We also have many Patient Assistance Programs in emerging markets, while offering access assistance in developed economies such as Europe and the U.S. We support differential pricing across lower-income countries to help access for patients in need of our therapies, and are committed to considering a country’s economic stage and health system maturity when pricing our medicines.


Polarization

The COVID-19 pandemic and growth of movements calling for social change worldwide have highlighted inequalities that continue to persist in society. Takeda believes that diversity, equity and inclusion are nonnegotiable — not only within the company, but also in the communities where we operate and serve patients. We’re committed to meeting the expectation that we are fair, equitable and nondiscriminatory as an employer.

All 10 of our colleague-led Takeda Resource Groups came together after recent global events related to racism and injustice to support each other and provide educational programs and resources to colleagues. These are meaningful platforms that provide an opportunity for open dialogue and change.

As a global company, we source materials from around the world. And we use our network to expand the diversity of our suppliers in a number of ways. Our Procurement Policy, for example, calls for including at least one small or diverse supplier in each request for proposal. It also requires our prime suppliers to provide second-tier reporting.


Speed of Innovation

Scientific and digital innovation are accelerating rapidly, offering enormous opportunities for companies to add value for patients and society. Health care companies need to stay on top of this trend, as patients are demanding more empowerment in their personalized care strategies.

Partnerships are a cornerstone of our strategy. Whether it’s in R&D or on the digital front, we believe that bringing the best minds together will deliver treatments even faster. Our focus remains on translating science into highly innovative, life-changing medicines that address unmet needs in four core
therapeutic areas — Oncology, Rare Genetic and Hematology, Neuroscience and Gastroenterology.

Our strategic collaboration with Accenture and Amazon Web Services will fuel Takeda’s cloud-driven business transformation by modernizing platforms, accelerating data services, establishing an internal engine for innovation and equipping Takeda’s employees with new skills and ways of working to realize our vision.

We’re in an industry where innovation is our lifeline. And the source of this innovation is our people. That’s why we strive to create a culture that encourages a mindset of lifelong learning and growth. Society demands greater transparency when it comes to scientific innovation, and we’re committed to responsible innovation, taking into consideration how our work affects patients, society, the planet and our business.


Global Warming

The effects of climate change on our planet, on human health and on the future way of life can be seen around the world on a daily basis. As a global company operating in about 80 countries, we know we must act urgently to combat climate change.

Because of the connection between the health of the planet and people, we’re making environmental stewardship and resource conservation central to our business operations and practices. This focus can also improve the way we operate through increased innovation and efficiency.

In 2020, Takeda announced that we would become carbon neutral and implement a long-term strategy
to reduce companywide emissions to zero by 2040. Our new Carbon Neutrality strategy will help us focus on reducing our carbon emissions over the next
two decades. This phased approach will allow us
to care for our patients and our planet for the long term, in collaboration with our business partners
and stakeholders.

We want our work environment to be one that’s part of a zero-carbon economy, with an environmentally conscious culture that attracts and retains the best talent. We’re equally committed to reducing our waste and our water consumption, and will continue to improve our materials and resources use in line with the principles of a circular economy.